Xencor Dirección
Dirección controles de criterios 3/4
El CEO de Xencor es Bassil Dahiyat , nombrado en Aug 1997, tiene una permanencia de 28.75 años. compensación anual total es $5.52M, compuesta por 13.5% salario y 86.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.49% de las acciones de la empresa, por valor de $4.54M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 8.8 años, respectivamente.
Información clave
Bassil Dahiyat
Chief Executive Officer (CEO)
US$5.5m
Compensación total
| Porcentaje del salario del CEO | 13.45% |
| Permanencia del CEO | 28.8yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 4.3yrs |
| Promedio de permanencia en la Junta Directiva | 8.8yrs |
Actualizaciones recientes de la dirección
Recent updates
XNCR: Refined Q4 Assumptions And Regulatory Shifts Will Drive Future Repricing
Analysts have kept Xencor's fair value estimate steady at $43.00, while modestly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E after recent research. This research includes a $1 price target increase to $27 from $26.00, alongside a downgrade based on expectations for fewer near term catalysts.
XNCR: Mixed Catalyst Outlook And Regulatory Shifts Will Shape Future Repricing
Analysts have increased their price target on Xencor by $1 to $27, citing updated models after the Q4 report, even as some see limited near term catalysts to significantly change the story. Analyst Commentary Recent research on Xencor reflects a more cautious tone, with some high profile firms highlighting limited catalysts and execution risk, even as models are refreshed following the Q4 report.XNCR: T Cell Engagers And Mixed Catalyst Outlook Will Shape Multi Year Repricing
Narrative Update The analyst fair value estimate for Xencor has been reset from $18.00 to $13.00 as analysts factor in a lack of near term, needle moving catalysts highlighted in recent research, along with updated models following the Q4 report and sector wide reassessments of U.S. biopharmaceutical valuations. Analyst Commentary Recent Street research on Xencor reflects a mix of views, and the reset in fair value has been driven mainly by more cautious commentary around the near term outlook and the timing of impactful catalysts.XNCR: Sector Tailwinds And T Cell Engagers Will Drive Multi Year Repricing
Analysts have nudged their Xencor models after recent sector-wide updates and the latest Q4 report, with Street price targets moving into a roughly $20 to $27 range. The internal fair value anchor in this framework holds near $18, reflecting tempered revenue and margin assumptions offset by supportive biopharma sentiment.XNCR: Reset Pipeline Milestones And Sector Tailwinds Will Drive Repricing
Analysts have raised their Xencor fair value estimate from $40.00 to $43.00, reflecting refreshed models and higher Street price targets, including recent moves to $27 and $20, supported by updated company assumptions and broader biotech sector drivers cited in recent research. Analyst Commentary Recent Street research on Xencor points to a more constructive stance on the stock, with bullish analysts revisiting their models after the latest quarterly update and broader sector checks.XNCR: T Cell Engagers In Solid Tumors Will Drive Multi Year Repricing
Analysts raised their Xencor price target to $20 from $17, citing an improving environment for U.S. biotech funding and deal activity, as well as greater market recognition of recent positive data catalysts. Analyst Commentary Recent commentary around Xencor frames the higher US$20 price target within a broader reassessment of U.S. biopharmaceutical names.Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate
Feb 13
XNCR: Constructive Biopharma Backdrop Will Support Future Oncology Upside
Narrative Update Analysts have nudged their 12 month price target for Xencor higher from US$17 to US$20, citing a more constructive backdrop for U.S. biopharmaceuticals, improving access to capital, supportive M&A activity, and recent positive data catalysts now being reflected in valuations. Analyst Commentary Recent commentary around Xencor centers on how it fits into a broader recovery in U.S. biopharmaceuticals, with the new US$20 price target reflecting both improved sector conditions and ongoing uncertainty about how durable these supports will be.XNCR: T Cell Engagers And TL1A Pipeline Will Drive Multi Year Repricing
Analysts have nudged their price targets on Xencor higher to a range of US$20 to US$42, pointing to positive recent data readouts, a more constructive view on the T cell engager and TL1A pipeline, and a generally more supportive biotech funding backdrop. Analyst Commentary Recent Street research on Xencor clusters around a more constructive view of its T cell engager and TL1A programs, but opinions are not uniformly bullish.XNCR: T Cell Engager Pipeline Progress Will Drive Multi Year Repricing Potential
Narrative Update Analysts have lifted their Xencor fair value estimate from US$8.67 to US$18.00. This change reflects higher Street price targets in the US$20 to US$42 range and growing confidence in the company's T cell engager pipeline following recent data updates and conference presentations.Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942
Jan 01XNCR: Advancing T Cell Engagers Will Drive Future Oncology Upside
We are nudging our Xencor fair value estimate slightly higher to $28.25 from $28.00, reflecting analysts' increased price targets and improved sentiment around the company's T cell engager and TL1A antibody programs following encouraging early stage data and clearer late stage development visibility. Analyst Commentary Recent Street research reflects a constructive but still risk balanced view on Xencor, with multiple firms lifting price targets as they factor in stronger T cell engager data and growing conviction in the TL1A program, while still highlighting execution and clinical readout risks that could impact long term value realization.XNCR: Advancing T Cell Engager Pipeline Will Drive Future Upside Potential
Xencor's analyst price target has inched higher to about $28.00 from roughly $27.91, as analysts factor in stronger long term value from the company's advancing T cell engager and TL1A antibody programs, despite modest tweaks to growth and margin assumptions. Analyst Commentary Recent Street research reflects a generally improving stance on Xencor, with several bullish analysts lifting price targets as confidence grows in the company’s T cell engager and TL1A programs, while more cautious voices continue to emphasize execution and clinical risk.There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 27% Share Price Rise
Nov 25XNCR: Advancing Late-Stage Antibody Programs Will Drive Upside Into 2025
The analyst price target for Xencor edged higher to $27.91 from $27.64 after analysts cited improved revenue growth outlook and progress across key clinical programs. Analyst Commentary Recent Street research on Xencor reflects a range of views, with several analysts updating their models and outlooks following new data from clinical programs and company updates.XNCR: Positive Early Oncology Data Will Accelerate Future Upside Potential
Xencor's analyst price target has increased from $25.73 to $27.64, with analysts citing positive pipeline updates and an improved outlook on novel oncology programs as drivers of the higher valuation. Analyst Commentary Analyst sentiment on Xencor has shifted notably in recent months, reflecting emerging data from clinical studies and evolving perspectives on the company's future growth potential.Analysts Weigh Xencor Pipeline Progress as Price Targets Inch Higher on Positive Data
The analyst price target for Xencor has increased modestly, rising by $0.18 per share as analysts cite encouraging initial data for its XmAb819 therapy and a slightly improved outlook on pipeline progress, despite ongoing development challenges. Analyst Commentary Recent Street research provides a mixed outlook on Xencor, reflecting both optimism around its emerging therapies and caution due to the company's ongoing development challenges and market execution risks.IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have raised their price target for Xencor from $24.10 to $25.55 per share. This reflects moderate optimism despite concerns around limited near-term catalysts and extended development timelines described in recent research commentary.There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise
Sep 25Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?
Sep 18IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have reduced their price target for Xencor to $25.20 amid optimism for key pipeline assets but tempered by concerns over limited data, lack of near-term catalysts, and execution speed. Analyst Commentary Stock price seen as undervaluing Xencor's three main business pillars: IBD franchise led by '942, immunology efforts led by plamotamab, and the oncology bispecific platform.Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking
Aug 06IBD Biologics And TL1A Programs Will Forge New Paths
Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability.Is Xencor (NASDAQ:XNCR) A Risky Investment?
Apr 26Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Mar 30Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%
Feb 04Xencor: Substantial Promise, Slow Progress
Jan 30Is Xencor (NASDAQ:XNCR) Using Too Much Debt?
Dec 31Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up
Dec 03Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 10Xencor: Vudalimab Development Along With Hidden Gem Candidate
Sep 12Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up
Sep 12Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Sep 06Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?
Jul 13Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S
Jun 16Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Mar 27There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Feb 27Xencor: Standing Out With XmAb Technology
Feb 03Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
Jan 05Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
Nov 13Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
Nov 10Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Aug 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2025 | US$6m | US$743k | -US$92m |
| Sep 30 2025 | n/a | n/a | -US$131m |
| Jun 30 2025 | n/a | n/a | -US$171m |
| Mar 31 2025 | n/a | n/a | -US$208m |
| Dec 31 2024 | US$7m | US$721k | -US$233m |
| Sep 30 2024 | n/a | n/a | -US$213m |
| Jun 30 2024 | n/a | n/a | -US$191m |
| Mar 31 2024 | n/a | n/a | -US$146m |
| Dec 31 2023 | US$8m | US$700k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$119m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$140m |
| Dec 31 2022 | US$8m | US$670k | -US$55m |
| Sep 30 2022 | n/a | n/a | US$30m |
| Jun 30 2022 | n/a | n/a | US$22m |
| Mar 31 2022 | n/a | n/a | US$109m |
| Dec 31 2021 | US$5m | US$625k | US$83m |
| Sep 30 2021 | n/a | n/a | -US$4m |
| Jun 30 2021 | n/a | n/a | US$24m |
| Mar 31 2021 | n/a | n/a | -US$64m |
| Dec 31 2020 | US$4m | US$600k | -US$69m |
| Sep 30 2020 | n/a | n/a | -US$83m |
| Jun 30 2020 | n/a | n/a | -US$80m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$567k | US$27m |
Compensación vs. Mercado: La compensación total de Bassil($USD5.52M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.59M).
Compensación vs. Ingresos: La compensación de Bassil ha sido consistente con los resultados de la empresa en el último año.
CEO
Bassil Dahiyat (55 yo)
28.8yrs
Permanencia
US$5,521,205
Compensación
Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 28.8yrs | US$5.52m | 0.49% $ 4.5m | |
| Senior VP & CFO | 2.1yrs | US$1.64m | 0.038% $ 351.8k | |
| Executive VP of Research & Chief Scientific Officer | 11.8yrs | US$1.98m | 0.29% $ 2.7m | |
| Senior VP | 6.7yrs | US$1.57m | 0.054% $ 498.0k | |
| Associate Director and Head of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Senior VIce President of Human Resources | 4.8yrs | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 4.3yrs | sin datos | sin datos | |
| Senior Vice President of Program Leadership & Alliance Management | 3.3yrs | sin datos | sin datos | |
| Executive VP & Chief Strategy Officer | 2.3yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development (Autoimmune) | less than a year | sin datos | sin datos |
4.3yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de XNCR se considera experimentado (4.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 28.8yrs | US$5.52m | 0.49% $ 4.5m | |
| Independent Director | 1.2yrs | US$624.80k | sin datos | |
| Independent Director | 8.4yrs | US$344.24k | 0.0075% $ 69.8k | |
| lead Independent Director | 11.2yrs | US$376.74k | 0.0094% $ 87.9k | |
| Independent Director | 9.1yrs | US$336.74k | 0.0071% $ 66.3k | |
| Director | less than a year | US$537.94k | sin datos | |
| Member of Scientific Advisory Board | 16.9yrs | sin datos | sin datos | |
| Independent Director | 7.5yrs | US$342.24k | 0.0075% $ 69.8k | |
| Independent Director | 11.8yrs | US$340.74k | 0.0089% $ 82.5k | |
| Independent Director | 2.7yrs | US$337.99k | 0% $ 0 |
8.8yrs
Permanencia media
68yo
Promedio de edad
Junta con experiencia: La junta directiva de XNCR se considera experimentada (8.8 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/04 18:27 |
| Precio de las acciones al final del día | 2026/05/01 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Xencor, Inc. está cubierta por 24 analistas. 13 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Zhiqiang Shu | Berenberg |